Aspergillus fumigatus is second only to Candida species as a cause of invasive fungal infections in immunocompromised humans. Current immunodiagnostic tests for invasive aspergillosis (IA) rely on the detection of circulating galactomannan (GM) in patient’s sera using a rat monoclonal antibody (mAb), EB-A2. Cross-reactivity of mAb EB-A2 with non-Aspergillus fungi, with contaminating GM in β -lactam antibiotics and foodstuffs and with bacterial lipoteichoic acids has prompted the discovery of non-GM antigens that can act as surrogate markers for the diagnosis of IA. We have generated a mouse mAb (JF5) that binds to an extracellular glycoprotein antigen secreted during active growth of A. fumigatus. The mAb was used to develop a lateral-flow device (LFD) for the rapid (15 min) detection of Aspergillus antigens in human serum. The test is highly specific reacting with Aspergillus species, but not with other clinically important fungi. The LFD was able to detect circulating Aspergillus antigen in serum samples from patients suspected or shown to have IA based on EORTC criteria and from serum tests for GM and fungal (18594;3)-β -d-glucan. The ease-of-use of the LFD provides a diagnostic platform for the routine testing of vulnerable patients who have an elevated risk of IA infection.
Full conference title:
Society of General Microbiology Meeting
- SGM 164th (2009)